andin vivodrug–drug interaction studies: a PhRMA perspective. J Clin Pharmacol
2003;43:443–469.
Cohen LH, Remley MJ, Raunig D, Vaz AD.In vitrodrug interactions of cytochrome
P450: an evaluation of fluorogenic to conventional substrates. Drug Metab Dispos
2003;31:1005–1015.
Davit B, Reynolds K, Yuan R, Ajayi F, Conner D, Fadiran E, Gillespie B, Sahajwalla
C, Huang SM, Lesko LJ. FDA evaluations usingin vitrometabolism to predict and
interpretin vivo metabolic drug–drug interactions: impact on labeling. J Clin
Pharmacol 1999;39:899–910.
de Graaf IAM, van Meijeren CE, Pektas F, Koster HJ. Comparison of in vitro
preparations for semiquantitative prediction ofin vivodrug metabolism. Drug Metab
Dispos 2002;30:1129–1136. DOI:10.1124/dmd.30.10.1129.
Dresser GK, Spence JD, Bailey DG. Pharmacokinetic–pharmacodynamic consequences
and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet
2000;38:41–57.
Ekins S, Williams JA, Murray GI, Burke MD, Marchant NC, Engeset J, Hawksworth
GM. Xenobiotic metabolism in rat, dog, and human precision-cut liver slices, freshly
isolated hepatocytes, and vitrified precision-cut liver slices. Drug Metab Dispos
1996;24:990–995.
Evans DC, Watt AP, Nicoll-Griffith DA, Baillie TA. Drug–protein adducts: an industry
perspective on minimizing the potential for drug bioactivation in drug discovery and
development. Chem Res Toxicol 2004;17:3–16.
Fennell TR, Kedderis GL, Sumner SCJ. Urinary metabolites of [1,2,3-^13 Cacrylonitrile
in rats and mice detected by^13 Cnuclear magnetic resonance spectroscopy. Chem Res
Toxicol 1991;4:678–687.
Fennell TR, Sumner SCJ. Identification of metabolites of carcinogens by^13 CNMR
spectroscopy. Drug Metab Rev 1994;26:469–481.
Ghibellini G, Leslie EM, Brouwer KL. Methods to evaluate biliary excretion of drugs in
humans: an updated review. Mol Pharmacol 2006;3:198–211.
Ghosal A, Hapangama N, Yuan Y, Lu X, Horne D, Patrick JE, Zbaida S. Rapid
determination of enzyme activities of recombinant human cytochromes P450, human
liver microsomes and hepatocytes. Biopharm Drug Dispos 2003;24:375–384.
Gomez-Lechon MJ, Donato MT, Castell JV, Jover R. Human hepatocytes as a tool for
studying toxicity and drug metabolism. Curr Drug Metab 2003;4:292–312.
Greenblatt DJ, von Moltke LL. Drug–drug interactions: clinical perspective. In:
Rodrigues AD, editor. Drug–Drug Interactions. New York: Marcel Dekker; 2002.
p 565–584.
Hall EJ. Radiobiology for the Radiologist. JB Lippincott Company; 1994.
Hewitt NJ, Utesch D. Cryopreserved rat, dog and monkey hepatocytes: measurement of
drug metabolizing enzymes in suspensions and cultures. Hum Exp Toxicol
2004;23:307–316.
Huang SM, Lesko LJ. Drug–drug, drug–dietary supplement, and drug–citrus fruit
and other food interactions: what have we learned? J Clin Pharmacol 2004;44:
559–569.
Iyer RA, Malhotra B, Sanaullah K, Mitroka J, Bonacorsi SJ, Waller SC, Rinehart JK,
Kripalani K. Comparative biotransformation of radiolabeled [^14 C]omapatrilat and
282 ROLE OF DRUG METABOLISM IN DRUG DEVELOPMENT